(Date:10/6/2008)...pecial supplement of the Oct. 15,journal Cancer fo...iddle-income countries to implement breast cancer ...se among women worldwide., "Guidelines for Intern...ntation" developed by the Breast Health Global Ini...e allocation -- based on countries,overall econom...
(Date:10/6/2008)...ently posted detailed information on its Cimzia in... side effects caused by the drug and its family kn...side effects are the development of fatal infectio...hild patients. , Denver, ...r one resource for everything and anything legal o...
(Date:10/6/2008)...ased civil litigation and criminal defense firm re...y awarded $3.2 million to plaintiff earlier this y...nd ((Lexis Nexis) October 6, 2008 -- Attorneys in ...Murtha & Psoras] have successfully resolved a ... welder who was awarded more than $3 million by a ...
(Date:10/5/2008)...elp detect serious bacterial infections (SBIs) lik...ions in young infants who come to the emergency de.... Researchers at Children,s Hospital Boston, colla...niversity, show that a new diagnostic marker calle...risk for SBIs while potentially reducing unnecessa...
Breaking Medicine News(10 mins):Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:New test could help catch serious infections in babies 2(Date:10/6/2008)...ct - Company,s Bioabsorbable Stent - Also,Slated f...- Data from multiple clinical trials ...,s Genous Bio-engineered R,stent, will be presente...erapeutics symposium, TCT 2008, in Washington, D.C...c Medical Center in,Amsterdam will provide a Genou...
(Date:10/3/2008)...wire-FirstCall/ -- Amsterdam Molecular,Therapeutic...gene therapy,announced today that it intends to i...orization Application (MAA) for Glybera(R) for Lip...ilitating and potentially lethal,disease., The da...ies (22,patients in total) demonstrate that Glyber...
(Date:10/2/2008)...sults of Rosetta Genomics, microRNA-based,Test, mi...From non Squamous non Small Cell Lung Cancer,...the miRview(TM) Technology First Approved for Clin...plexity Molecular Pathology Lab ...pecting to Launch miRview(TM) Squamous Later This ...
(Date:10/2/2008)...wire/ -- Athera Biotechnologies AB and Dyax,Corp. ...ered into a,collaboration to discover and to devel...tment of cardiovascular inflammatory diseases., T... work by Athera,scientific founders, Professors Fr.... The research links naturally occurring antibodie...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4National Long Term Care Leaders to Release New Data Discuss Negative National Economic Jobs Impact 18955 1AutoImmune Inc Reports 2008 First Quarter Financial Results 18952 1AutoImmune Inc Reports 2008 First Quarter Financial Results 18952 2AutoImmune Inc Reports 2008 First Quarter Financial Results 18952 3Web Site Helps Patients Prepare for Hospital Stay 18948 1Web Site Helps Patients Prepare for Hospital Stay 18948 2Web Site Helps Patients Prepare for Hospital Stay 18948 3Development of new techniques to understand marble quality and durability 3248 1Development of new techniques to understand marble quality and durability 3248 2...ON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - Columbia... that preliminary,results from the ongoing data an...bo-controlled, double-blind Phase III clinical,tri...revention of,preterm birth in women with a previou...s revealed a possible effect of PROCHIEVE 8%,in de...
... Australia, April 26, 2007 /PRNewswire-FirstCall/ ...mited today,announced preliminary results from its...th metastatic colorectal cancer, where,Alchemia,s ...s,considered to be a cornerstone drug for the trea...eing made at a preliminary stage of,the analysis i...
Other Medicine Technology:Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7This new dedicated VICTOR2 model is for fluorescence and luminescence measurements.
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading.
The basic modular version of the VICTOR2 multilabel counter for fluorescence, luminescence and absorption measurements, with the stacker and the robotic loading configuration.
Medicine Products: